Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.47 |
| ▸ | BAZ2B | Q9UIF8 | 1/20 | 0.44 |
| ▸ | BAZ2A | Q9UIF9 | 1/20 | 0.44 |
| ▸ | CA12 | O43570 | 3/20 | 0.42 |
| ▸ | CA1 | P00915 | 3/20 | 0.42 |
| ▸ | CA2 | P00918 | 3/20 | 0.42 |
| ▸ | CA7 | P43166 | 3/20 | 0.42 |
| ▸ | CA9 | Q16790 | 3/20 | 0.42 |
| ▸ | CA14 | Q9ULX7 | 3/20 | 0.42 |
| ▸ | POLB | P06746 | 2/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.41 |
| ▸ | XDH | P47989 | 2/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.41 |
| ▸ | LMNA | P02545 | 2/20 | 0.41 |
| ▸ | GAA | P10253 | 2/20 | 0.41 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.41 |
| ▸ | GFER | P55789 | 1/20 | 0.41 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.41 |
| ▸ | RELA | Q04206 | 1/20 | 0.41 |
| ▸ | FUT7 | Q11130 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7504401 | 0.84 | ALDH1A1 (0.43) | ALDH1A1BAZ2BBAZ2ACA12CA1 | |
| SCHEMBL16329647 | 0.81 | CA12 (0.47) | ALDH1A1CA12CA1CA2CA7 | |
| SCHEMBL6968268 | 0.79 | NOTUM (0.38) | LMNAL3MBTL1 | |
| SCHEMBL77311 | 0.76 | NOTUM (0.59) | ALDH1A1BAZ2BBAZ2ACA12CA1 | |
| SCHEMBL1079476 | 0.76 | NOTUM (0.54) | ALDH1A1CA12CA1CA2CA7 | |
| SCHEMBL28140578 | 0.76 | SMN1; SMN2 (0.42) | ALDH1A1BAZ2BBAZ2AKDM4ELMNA | |
| Formic Acid SCHEMBL31187369 | 0.75 | ALDH1A1 (0.42) | ALDH1A1BAZ2BBAZ2ACA12CA1 | |
| SCHEMBL9788937 | 0.75 | ALDH1A1 (0.37) | ALDH1A1KDM4ETDP1GAA | |
| SCHEMBL9921966 | 0.75 | CDC7 (0.43) | ALDH1A1POLBTDP1L3MBTL1ERN1 | |
| SCHEMBL70354 | 0.75 | BAZ2B (0.71) | ALDH1A1BAZ2BBAZ2ACA12CA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 72 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0623619-B1 | PREPARATION METHOD OF ARENO[e]INDOLS | PHARMA MAR S A PHARMAR (ES) | 1999-02-03 | — | — | EP | claimed |
| US-5571927-A | Areno [E]indols, preparation method and application as intermediates in the synthesis of products with antitumoral activity | PHARMA-MAR, S.A.- PHARMAR (ES) | 1996-11-05 | — | — | US | claimed |
| EP-0623619-A1 | NEW ARENO[e]INDOLS, PREPARATION METHOD AND APPLICATION AS INTERMEDIATES IN THE SYNTHESIS OF PRODUCTS WITH ANTITUMORAL ACTIVITY | PHARMA-MAR S.A.-PHARMAR (ES) | 1994-11-09 | — | — | EP | claimed |
| EP-4029868-B1 | MCL-1 INHIBITORS | GILEAD SCIENCES INC (US) | 2026-05-20 | — | — | EP | disclosed |
| US-12509453-B2 | BRM/BRG1 inhibitors and uses thereof | FOGHORN THERAPEUTICS INC. (US) | 2025-12-30 | — | — | US | disclosed |
| US-20250197421-A1 | MCL1 INHIBITORS | GILEAD SCIENCES, INC. | 2025-06-19 | — | — | US | disclosed |
| US-12202842-B2 | MCL1 inhibitors | GILEAD SCIENCES, INC. (US) | 2025-01-21 | — | — | US | disclosed |
| CN-114867530-B | MCL1 inhibitors | 吉利德科学公司 | 2024-08-16 | — | — | CN | disclosed |
| CN-117304130-A | MCL-1 inhibitors | 吉利德科学公司 | 2023-12-29 | — | — | CN | disclosed |
| US-20230348494-A1 | MCL1 INHIBITORS | GILEAD SCIENCES, INC. | 2023-11-02 | — | — | US | disclosed |
| US-20230348494-A1 | MCL1 INHIBITORS | GILEAD SCIENCES, INC. | 2023-11-02 | — | — | US | disclosed |
| EP-0623619-B1 | PREPARATION METHOD OF ARENO[e]INDOLS | PHARMA MAR S A PHARMAR (ES) | 1999-02-03 | — | — | EP | disclosed |
| WO-1997041115-A1 | 5,6,7,8-TETRAHYDROPYRIDO[2,3-d]PYRIMIDINES | THE TRUSTEES OF PRINCETON UNIVERSITY (US) | 1997-11-06 | — | — | WO | disclosed |
| US-5631384-A | Areno [e]indols, preparation method and application as intermediates in the synthesis of products with antitumoral activity | PHARMA-MAR, S.A.-PHARMAR (ES) | 1997-05-20 | — | — | US | disclosed |
| US-5571927-A | Areno [E]indols, preparation method and application as intermediates in the synthesis of products with antitumoral activity | PHARMA-MAR, S.A.- PHARMAR (ES) | 1996-11-05 | — | — | US | disclosed |
| EP-0623619-A1 | NEW ARENO[e]INDOLS, PREPARATION METHOD AND APPLICATION AS INTERMEDIATES IN THE SYNTHESIS OF PRODUCTS WITH ANTITUMORAL ACTIVITY | PHARMA-MAR S.A.-PHARMAR (ES) | 1994-11-09 | — | — | EP | disclosed |
| EP-0077024-B1 | IMIDAZOLE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL PRODUCTS CONTAINING THEM | SCHERING AKTIENGESELLSCHAFT (DE) | 1987-08-12 | — | — | EP | disclosed |
| US-4585771-A | Antiinflammatory imidazole derivatives | SCHERING AKTIENGESELLSCHAFT (DE) | 1986-04-29 | — | — | US | disclosed |
| US-4466976-A | Antiinflammatory and antiallergic imidazole derivatives | SCHERING AKTIENGESELLSCHAFT (DE) | 1984-08-21 | — | — | US | disclosed |
| EP-0077024-A2 | Imidazole derivatives, process for their preparation and pharmaceutical products containing them | SCHERING AKTIENGESELLSCHAFT (DE) | 1983-04-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12202842-B2 | MCL1 inhibitors | MCL1, BCL2L1, BCLAF1 | ALDH1A1 887/4885BAZ2B 1150/4885BAZ2A 1024/4885 |
| US-20230348494-A1 | MCL1 INHIBITORS | MCL1, BCL2L1, BCLAF1 | ALDH1A1 946/4885BAZ2B 1061/4885BAZ2A 906/4885 |
| US-12509453-B2 | BRM/BRG1 inhibitors and uses thereof | SMARCC1, SMARCC2, SMARCA1 | ALDH1A1 2651/4885BAZ2B 31/4885BAZ2A 22/4885 |
| US-20250197421-A1 | MCL1 INHIBITORS | MCL1, BCL2L1, BCLAF1 | ALDH1A1 946/4885BAZ2B 1061/4885BAZ2A 906/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.